Titlebook: Renal Cell Carcinoma; Molecular Features a Mototsugu Oya Book 2017 Springer Japan KK 2017 Molecular-targeted therapy.TKI.anti-angiogenic ag

使無罪

書目名稱Renal Cell Carcinoma影響因子(影響力)




書目名稱Renal Cell Carcinoma影響因子(影響力)學科排名




書目名稱Renal Cell Carcinoma網(wǎng)絡公開度




書目名稱Renal Cell Carcinoma網(wǎng)絡公開度學科排名




書目名稱Renal Cell Carcinoma被引頻次




書目名稱Renal Cell Carcinoma被引頻次學科排名




書目名稱Renal Cell Carcinoma年度引用




書目名稱Renal Cell Carcinoma年度引用學科排名




書目名稱Renal Cell Carcinoma讀者反饋




書目名稱Renal Cell Carcinoma讀者反饋學科排名

我怕被刺穿

Melatonin

Molecular Genetics of Renal Cell Carcinoma,and whole-genome sequencing, the genomic landscapes of renal cell carcinoma (RCC), consisting mainly of clear-cell, papillary (1 and 2), and chromophobe subtypes, have been characterized. This genomic information, coupled with DNA methylation, has shed light on the molecular biology of RCC and creat

Ptsd429

預防注射

Imaging Features of Renal Cell Carcinoma Differential Diagnosis, Staging, and Posttreatment Evaluatection of various subtypes of renal cell carcinomas (RCCs) and benign renal tumors. The differentiation of RCCs from benign tumors such as fat-poor angiomyolipoma and oncocytoma is very important to prevent unnecessary surgery. In addition, the recent progress of therapies to treat RCCs, including n

Fester

外觀

Natural History and Active Surveillance,is seen in cancers less than 4?cm. Surgery, either radical or partial nephrectomy, has been the mainstay of treatment of a small renal mass (SRM), defined as a usually incidentally discovered renal mass <4?cm in diameter which enhances on contrast imaging. There is morbidity associated with this sta

和平主義者

Surgical Treatment for Renal Cell Carcinoma,f renal cell carcinoma is an integral component of oncologic management. The spectrum of renal cell carcinoma presentation from small renal masses, locally advanced disease, and in the presence of metastasis varies with the surgical armamentarium needed to treat this diverse group of patients. In ge

GROG

廢墟

Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib,ant improvement in patient outcomes. To date, targeting the vascular endothelial growth factor receptor (VEGFR) has been shown to lead to improved clinical outcomes in metastatic RCC. Currently, four VEGFR tyrosine kinase inhibitors (TKIs) have been approved by the Food and Drug Administration (FDA)